AbstractObjective To investigate the correlation between the expression of serum long-chain non-coding RNA (lncRNA) H19 and prognosis in patients with colorectal cancer.Methods Eighty-six patients with colorectal cancer who underwent radical operation and adjuvant chemotherapy in our hospital from January 2013 to December 2015 were selected as the study subjects (observation group). 90 volunteers who underwent physical examination in our hospital during the same period were selected as the control group. The expression level of lncRNA H19 in serum of the two groups was detected by qRT-PCR, and the correlation between the expression level of lncRNA H19 in serum of the observation group and the effect of chemotherapy was analyzed. Results The results of qRT-PCR showed that the level of serum lncRNA H19 in the observation group was (1.63±0.35) significantly higher than that in the control group (1.00 ± 0.11), and the difference was statistically significant (t = 16.259,P<0.01). The critical value 2.03 was set as the median level of serum lncRNA H19 expression in the observation group, and the patients were divided into two groups: high expression group and low expression group, 43 cases in each group. The maximum diameter, low differentiation, lymph node metastasis, invasion of serosa, the proportion of stage Ⅲ~Ⅳ and preoperative CEA level in the high expression group were significantly higher than those in the low expression group (P<0.05). There was no significant difference in the incidence of gastrointestinal discomfort, bone marrow sup-pression, liver and kidney dysfunction, neurotoxicity and mucositis between the high and low expression groups after chemotherapy (P>0.05). The median total survival time (OS) and progression-free survival (PFS) in the high-expression group were 33.6 months and 22.9 months respectively, which were significantly lower than those in the low-expression group (55.8 months and 43.3 months), with statistical significance (P<0.05).Conclusion The survival of patients with high expression of serum lncRNA H19 in colorectal cancer is poor, and the sensitivity of post-operative chemotherapy is lower, but there is no significant correlation with chemotherapy tolerance.
[1] 中华人民共和国卫生和计划生育委员会医政医管局,中华医学会肿瘤学分会.中国结直肠癌诊疗规范(2017年版)[J].中国医学前沿杂志(电子版),2018,10(3):1-21. [2] 刘东楠,张锦辉,夏荣钧,等.检测结直肠癌患者血清中长链非编码RNA-SchLAP1和DEK表达的临床意义[J].辽东学院学报(自然科学版),2017,24(2):120-124. [3] 杨襄蓉,魏春山,刘婵,等.lncRNA BC002811对胃癌细胞侵袭转移能力的影响[J].医学临床研究,2018,35(9):1679-1682. [4] 王晴美,谢亚莉,陈婷,等.长链非编码RNA参与结直肠癌转移途径的相关研究[J].转化医学电子杂志,2018,5(5):33-38. [5] 林映汐,陶华林.血浆外泌体非编码RNA H19在乳腺癌中的诊断价值[J].临床检验杂志,2018,36(2):99-101. [6] 程卓夫,余淦,王志华,等.长链非编码RNA H19通过抑制CCND2促进膀胱癌细胞增殖的分子机制[J].现代泌尿生殖肿瘤杂志,2018,10(2):118-122. [7] 尤梁惠,刘志军,德伟,等.长链非编码RNA H19促进人胃癌MGC-803细胞增殖的实验研究[J].临床肿瘤学杂志,2014,(9):774-778. [8] 王珏,张尤历,徐岷,等.长链非编码 RNA H19对胰腺癌细胞增殖、侵袭及转移的影响[J].江苏大学学报(医学版),2016,26(6):475-479,483. [9] 周含,孙亚男.肿瘤相关基因LncRNA H19的研究进展[J].现代肿瘤医学,2016,24(11):1822-1826. [10] 霍小蕾,裴振,李永芝,等.长链非编码RNA H19促进结直肠癌细胞株增殖的研究[J].四川大学学报(医学版),2017,48(6):844-849. [11] Han D, Gao X, Wang M,et al. Long noncoding RNA H19 indicates a poor prognosis of colorectal cancer and promotes tumor growth by recruiting and biding to eIF4a3 [J].Oncotarget,2016,7(16):22159-22173. [12] Liang WC, Fu WM, Wong CW, et al. The lncRNA H19 promotes epithelial to mesenchymal transition by functioning as miRNA sponges in colorectal cancer [J].Oncotarget,2015,6(26):22513-22525. [13] 曹宇勃,许崇安,刘殊,等.改良FOLFOX方案治疗晚期结直肠癌的临床研究[J].现代肿瘤医学,2009,17(2):285-287. [14] 高宗跃,周晓丽.XELOX与FOLFOX4治疗方案对老年转移性结直肠癌序贯化疗的效果[J].中国老年学杂志,2018,38(15):3641-3643. [15] 王秀梅,赵海平,秦琼,等.长非编码RNA H19在结直肠癌化疗敏感性中的作用研究[J].中华结直肠疾病电子杂志,2018,7(5):437-441.
2019, Vol. 36 
